Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/46950
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss
Author: Bowen, J.
Stringer, A.
Gibson, R.
Yeoh, A.
Hannam, S.
Keefe, D.
Citation: Cancer Biology & Therapy, 2007; 6(9):1449-1454
Publisher: Landes Bioscience
Issue Date: 2007
ISSN: 1538-4047
1555-8576
Statement of
Responsibility: 
Joanne M Bowen, Andrea M Stringer, Rachel J Gibson, Ann SJ Yeoh, Sarah Hannam and Dorothy MK Keefe
Abstract: Background: One of the most common toxicities of cancer treatment is diarrhoea. Probiotics have been shown effective at preventing diarrhoea in inflammatory bowel disease and may prove useful in the oncology setting. Aim: The primary aim of this study was to investigate the probiotic mixture, VSL#3, for amelioration of chemotherapy-induced diarrhoea (CID). Methods: This experiment was carried out in a clinically relevant model of CID. VSL#3 was administered to female DA rats in one of three schedules. Irinotecan was used to induce mucositis and diarrhoea, with rats monitored for 7 days to record incidence of weight-loss and diarrhoea. At study completion, intestines were collected to investigate histological and proliferative changes, apoptosis levels and mucin composition. Results: VSL#3 reduced weight loss following irinotecan when administered before and after chemotherapy. Moderate and severe diarrhoea was also prevented in these rats. This was associated with a significant increase in crypt proliferation combined with an inhibition of apoptosis in both the small and large intestines. VSL#3 also prevented irinotecan-induced increases in goblet cells within jejunal crypts. Conclusions: VSL#3 is effective at preventing severe diarrhoea following chemotherapy with irinotecan and therefore has potential to be used clinically by cancer patients.
Keywords: Goblet Cells; Animals; Humans; Rats; Neoplasms; Diarrhea; Mucins; Antineoplastic Agents; Organ Size; Treatment Outcome; In Situ Nick-End Labeling; Apoptosis; Probiotics; Female; Mucositis
Description: © 2007 Landes Bioscience
RMID: 0020074741
DOI: 10.4161/cbt.6.9.4622
Published version: http://www.landesbioscience.com/journals/cbt/article/4622
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.